Catalyst Pharmaceuticals, Inc. (CPRX)
NASDAQ: CPRX · IEX Real-Time Price · USD
14.68
-0.44 (-2.91%)
At close: Apr 25, 2024, 4:00 PM
14.62
-0.06 (-0.41%)
After-hours: Apr 25, 2024, 7:58 PM EDT
Catalyst Pharmaceuticals Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for CPRX stock have an average target of 26.83, with a low estimate of 23 and a high estimate of 34. The average target predicts an increase of 82.77% from the current stock price of 14.68.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 27, 2024.
Analyst Ratings
The average analyst rating for CPRX stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 4 | 4 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 4 | 4 | 4 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Reiterates $29 | Buy | Reiterates | $29 | +97.55% | Mar 27, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $34 | Buy | Reiterates | $34 | +131.61% | Mar 22, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $34 | Buy | Reiterates | $34 | +131.61% | Mar 14, 2024 |
| Citigroup | Citigroup | Strong Buy Initiates $27 | Strong Buy | Initiates | $27 | +83.92% | Mar 14, 2024 |
| B of A Securities | B of A Securities | Strong Buy Initiates $23 | Strong Buy | Initiates | $23 | +56.68% | Mar 7, 2024 |
Financial Forecast
Revenue This Year
472.93M
from 398.20M
Increased by 18.77%
Revenue Next Year
564.03M
from 472.93M
Increased by 19.26%
EPS This Year
1.06
from 0.63
Increased by 68.06%
EPS Next Year
1.49
from 1.06
Increased by 40.85%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 501.8M | 634.8M | 746.6M | 612.1M | 575.2M |
| Avg | 472.9M | 564.0M | 640.4M | 585.9M | 558.8M |
| Low | 446.4M | 507.6M | 530.5M | 554.5M | 536.8M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 26.0% | 34.2% | 32.4% | -4.4% | -1.8% |
| Avg | 18.8% | 19.3% | 13.5% | -8.5% | -4.6% |
| Low | 12.1% | 7.3% | -6.0% | -13.4% | -8.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 1.30 | 1.82 | 1.99 | 2.88 |
| Avg | 1.06 | 1.49 | 1.66 | 2.79 |
| Low | 0.83 | 1.23 | 1.38 | 2.69 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 106.7% | 71.6% | 33.8% | 73.8% |
| Avg | 68.1% | 40.8% | 11.0% | 68.8% |
| Low | 32.2% | 15.7% | -7.3% | 62.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.